Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 14 h ago

Immatics N.V.: BAKER BROS. ADVISORS LP amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Baker Bros. Advisors LP amended its Schedule 13G filing on Immatics N.V., disclosing a change to its passive stake in the Nasdaq-listed biotech under SEC accession 0001104659-26-128332. The filing, submitted to the U.S. Securities and Exchange Commission, updates the institutional investor's previously reported position in the company. The amendment does not, on its face, indicate activist intent, as Schedule 13G is reserved for passive holders. The disclosure matters because Baker Bros. is a specialist healthcare investor whose positioning in Immatics can signal institutional sentiment toward the company's TCR-based cancer therapies. Investors will watch for the specific share count and percentage in the amended filing, and for any subsequent 13F or 13G updates that clarify whether the change reflects accumulation or reduction.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Baker Bros. Advisors LP, Immatics N.V.